RT Journal Article
SR Electronic
T1 Osteosarcoma of the Breast in a Patient Derived Orthotopic Xenograft (PDOX) Mouse Model Is Arrested by both Cisplatinum and Eribulin
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 3107
OP 3110
DO 10.21873/invivo.12605
VO 35
IS 6
A1 NORIYUKI MASAKI
A1 NATHANIEL F. WU
A1 YUSUKE AOKI
A1 JUN YAMAMOTO
A1 JUN MIYAZAKI
A1 ROBERT M. HOFFMAN
YR 2021
UL http://iv.iiarjournals.org/content/35/6/3107.abstract
AB Background/Aim: Primary osteosarcoma of the mammary gland is a very rare disease, accounting for less than 1% of all mammary malignancies. There is no established first-line treatment and the prognosis is poor compared to normal breast cancer. We previously established the first patient tumor-derived animal model of this disease, grown subcutaneously in nude mice. In the present study, we established a patient derived orthotopic xenograft (PDOX) model of osteosarcoma of the breast and investigated the efficacy of cisplatinum (CDDP) and eribulin (ERB). Materials and Methods: PDOX models of primary osteosarcoma of the breast were divided into 3 groups (5-6 mice per group): untreated control; CDDP treatment; ERB treatment. The tumor volume in the 3 groups was compared after 2 weeks. Results: There were significant differences between control and CDDP, and control and ERB (p=0.036, 0.046, respectively). However, there was no significant difference between CDDP and ERB (p=0.964). Conclusion: CDDP and ERB are candidates for first-line clinical therapy of primary osteosarcoma of the breast.